A 32-year-old man from rural Maharashtra presents to the emergency department with a 5-day history of progressive weakness starting in the lower limbs and ascending to involve the upper limbs and facial muscles. He reports a diarrheal illness 2 weeks prior that resolved spontaneously. On examination, he has symmetrical flaccid paralysis of the legs (MRC grade 2/5) and arms (grade 3/5), absent deep tendon reflexes, and mild facial weakness bilaterally. Respiratory rate is 22/min. CSF analysis shows protein 85 mg/dL with normal cell count and glucose. Nerve conduction studies show prolonged distal latencies and conduction blocks. What is the most appropriate immediate management?

Explanation

## Clinical Diagnosis: Guillain-Barré Syndrome (GBS) **Key Point:** This patient presents with the classic triad of GBS: ascending paralysis, areflexia, and albuminocytologic dissociation (elevated CSF protein with normal cell count). The preceding diarrheal illness (likely *Campylobacter jejuni*) is a well-recognized trigger. **High-Yield:** GBS is the most common cause of acute flaccid paralysis worldwide and requires urgent immunomodulatory therapy to prevent respiratory failure and reduce disability. ### Why IVIg is the Answer **Clinical Pearl:** Both IVIg and plasmapheresis are first-line treatments with equivalent efficacy when given early (within 2 weeks of symptom onset). IVIg is preferred in most settings because: - Easier to administer (peripheral IV access) - Fewer complications (no need for vascular access, no volume shifts) - Better tolerated in resource-limited settings - Faster to initiate **Mnemonic: IVIG Advantages — EASE** - **E**asy access (peripheral IV) - **A**void complications (no central line) - **S**table hemodynamics - **E**arly response (same efficacy as plasmapheresis) ### Treatment Algorithm ```mermaid flowchart TD A[GBS suspected: ascending paralysis + areflexia]:::outcome --> B{Respiratory compromise?}:::decision B -->|Yes, RR > 25 or FVC < 20 mL/kg| C[ICU admission + prepare for intubation]:::urgent B -->|No| D[Start immunotherapy within 2 weeks]:::action D --> E{Access/contraindications?}:::decision E -->|Good IV access, no IgA deficiency| F[IVIg 2 g/kg over 3–5 days]:::action E -->|Central line available, fluid overload risk| G[Plasmapheresis 5 exchanges]:::action F --> H[Monitor respiratory function daily]:::action G --> H H --> I[Supportive care: DVT prophylaxis, nutrition, PT/OT]:::action ``` ### Dosing & Duration | Parameter | IVIg | Plasmapheresis | |-----------|------|----------------| | **Dose** | 2 g/kg total | 1–1.5 plasma volumes per exchange | | **Duration** | 3–5 days | 5 exchanges over 7–10 days | | **Efficacy** | ~85% improve within 4 weeks | ~85% improve within 4 weeks | | **Onset** | 3–7 days | 3–7 days | | **Contraindications** | IgA deficiency (anaphylaxis risk) | Hemodynamic instability, thrombocytopenia | **Key Point:** Corticosteroids are NOT beneficial in GBS and may worsen outcomes — avoid. Mechanical ventilation is supportive only and does not modify disease course. [cite:Harrison 21e Ch 379]